{
    "id": 32851,
    "fullName": "ERBB2 V604_E619del",
    "impact": "deletion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) V604_E619del results in the deletion of 16 amino acids in the extracellular domain of the Erbb2 (Her2) protein from amino acids 604 to 619 (UniProt.org). V604_E619del results in constitutive phosphorylation of Erbb2 (Her2), Egfr, Mek1/2, and Mapk, and is transforming in cell culture (PMID: 31135266).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "V604_E619del",
    "createDate": "03/21/2020",
    "updateDate": "03/21/2020",
    "referenceTranscriptCoordinates": {
        "id": 188598,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39717393_39717440del48",
        "cDna": "c.1811_1858del48",
        "protein": "p.V604_E619del16",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21055,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited Erbb2 signaling and viability of transformed breast epithelial cells expressing ERBB2 (HER2) V604_E619del in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 35523,
                "profileName": "ERBB2 V604_E619del"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21054,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited Erbb2 signaling and viability of transformed breast epithelial cells expressing ERBB2 (HER2) V604_E619del in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 35523,
                "profileName": "ERBB2 V604_E619del"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35523,
            "profileName": "ERBB2 V604_E619del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188597,
            "transcript": "NM_001005862",
            "gDna": "chr17:g.39719788_39723319del3532",
            "cDna": "c.1810_1857del3532",
            "protein": "p.C604_S619del16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 188596,
            "transcript": "NM_001289936",
            "gDna": "chr17:g.39717438_39719791del2354",
            "cDna": "c.1811_1858del2354",
            "protein": "p.E604_C619del16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 188599,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39717393_39717440del48",
            "cDna": "c.1811_1858del48",
            "protein": "p.V604_E619del16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 188598,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39717393_39717440del48",
            "cDna": "c.1811_1858del48",
            "protein": "p.V604_E619del16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}